andr4 😎 🇩🇪

AI / XR 🫶🏻

[andr4 😎 🇩🇪 @andr4andr4andr4]

@_kittypunk Ich habe von '98 - 2001 dort gearbeitet.
Ihr habt ja keine Vorstellung was dort TÄGLICH über den Ladentisch ging.
Man... war das eine verrückte Zeit.

[andr4 😎 🇩🇪 @andr4andr4andr4]

@ryanbrewer Who would have thought ?

[Lifespan @JoinLifespan]

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀

Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman

The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases

The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression

“This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”

Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.

“This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.”

Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment

Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies.

Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform.

About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults

While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments

About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at https://t.co/GDRzIctoot (NCT07290244): https://t.co/Jj9cnu2M6w

For more information, visit https://t.co/msih0JTYfF or follow on social media
https://t.co/pEGPJjFjnQ

[andr4 😎 🇩🇪 @andr4andr4andr4]

@CuriosityonX Religion

[gabriel @gabriel1]

i have resigned from openai

i left sora early this year to start a team at openai to build something great. but i've always been a founder, and there is one last product i need to build before AGI

already miss all my friends and Colleague(s), i believe in you! more soon

[andr4 😎 🇩🇪 @andr4andr4andr4]

@TinoStrussoAfD Vielleicht hat er Tomaten am Auspuff.

[andr4 😎 🇩🇪 @andr4andr4andr4]

@elonmusk There's something in the water !!! ... and food

[andr4 😎 🇩🇪 @andr4andr4andr4]

@BiancoDavinci

[Markus J. Buehler @ProfBuehlerMIT]

We've made a breakthrough in self-evolving AI scientists moving from "search" to "principled discovery": Scientific discovery requires that the search space itself changes, and an AI scientist must perceive this shift without intervention. We built an AI that achieves this for the first time with the ability to discover the scientific vocabulary it reasons in. Evidence, tools, artifacts, verifiers, failures & claims become typed provenance. We show three distinct modalities: 1) retrieval, adding known objects; 2) search, exploring a fixed schema; and critically: 3) discovery, a verified regime transition.

We solve the open-endedness evaluation problem by lifting agentic workflows into a typed copresheaf and proving, via a Kan obstruction, that true discovery is not unbounded generation but a verifiable schema expansion: old evidence is transported by Left Kan extension, and genuine novelty is mathematically quantified by the pointwise residual beyond the transported image - separating discovery from mere search and making novelty objective and measurable rather than a subjective judgment or benchmark delta.

Our AI scientist is built in a way that does not pre-conceive the approach it chooses; instead, we endow the system with formal power to adapt, evolve, and reason from first principles. Case studies include:
1⃣Builder/Breaker model that discovers mode-conditioned compliance in proteins;
2⃣CategoryScienceClaw that finds anisotropic fiber-network stiffness rules.

Great work in collaboration with my graduate student @fwang108_ @MITdeptofBE

F.Y. Wang & M.J. Buehler, Self-Revising Discovery Systems for Science: A Categorical Framework for Agentic Artificial Intelligence, arXiv:2606.01444, 2026

[andr4 😎 🇩🇪 @andr4andr4andr4]

@osanseviero When Windows ?

[MTS @MTSlive]

SITUATION DETECTED: For the first time in internet history, agentic traffic has surpassed human traffic online, per Cloudflare Radar.

[andr4 😎 🇩🇪 @andr4andr4andr4]

@politico 🕊️

[andr4 😎 🇩🇪 @andr4andr4andr4]

@sama That is a massive understatement.

[andr4 😎 🇩🇪 @andr4andr4andr4]

@ianzelbo @CharlesPattson It's both

[andr4 😎 🇩🇪 @andr4andr4andr4]

@AnishKattukaran Endlich ... Danke

[andr4 😎 🇩🇪 @andr4andr4andr4]

@disclosureday That animation for a Blockbuster Movie 🫣

[Ricky Wang @ryw999]

We’re hiring for robotics at OpenAI. Come join us building physical AGI with an incredible team!

[andr4 😎 🇩🇪 @andr4andr4andr4]

@Bitcoin_Teddy https://t.co/U970jeLinx

[andr4 😎 🇩🇪 @andr4andr4andr4]

@GithubProjects @grok

[andr4 😎 🇩🇪 @andr4andr4andr4]

@cb_doge https://t.co/oJ1txSnN9E